臨床外科69巻6号

2014年06月発行

特集 癌の補助療法アップデート

膵癌に対する術前補助療法

著者： 吉富秀幸¹ 清水宏明¹ 大塚将之¹ 加藤厚¹ 古川勝規¹ 高屋敷吏¹ 久保木知¹ 岡村大樹¹ 鈴木大亮¹ 酒井望¹ 中島正之¹ 宮崎勝¹

所属機関： ¹千葉大学大学院医学研究院臓器制御外科学

ページ範囲：P.700 - P.706

【ポイント】

◆膵癌では早期より微小転移が発生している可能性があり，集学的治療法が治療成績の向上に重要と考えられる．

◆術前化学療法により早期から補助療法を導入することで，治療成績の向上に役立つと考えられるが，今後の臨床試験の結果を待つ必要がある．

◆切除困難と考えられた局所進行膵癌に，化学（放射線）療法により腫瘍縮小をはかり外科切除を行うdown staging療法が有用である．

参考文献

1）Imamura M, Doi R, Imaizumi T, et al：A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 136：1003-1011, 2004

2）Burris 3rd HA, Moore MJ, Anderson J, et al：Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer：a randomized trial. J Clin Oncol 15：2403-2413, 1997

3）Rhim AD, Mirek ET, Aiello NM, et al：EMT and dissemination precede pancreatic tumor formation. Cell 148：349-361, 2011

4）Rhim AD, Thege FI, Santana SM, et al：Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology 146：647-651, 2014

5）Pedrazzoli S, DiCarlo V, Dionig R, et al：Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas：a multicenter, prospective randomized study. Ann Surg 228：508-517, 1998

6）Yeo CY, Cameron JL, Lillemoe KD, et al：Pancreaticoduodenectomy with or eithout distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2. Ann Surg 236：355-368, 2002

7）Farnell MB, Pearson RK, Sarr MG, et al：A prospective randomized trical comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in respectable pancreatic head adenocarcinoma. Surgery 138：618-630, 2005

8）Nimura Y, Nagino M, Takao S, et al：Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas：long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19：230-241, 2012

9）Oettle H, Post S, Neuhaus P, et al：Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 297：267-277, 2007

10）Yoshitomi H, Togawa A, Kimura F, et al：A randomized phase Ⅱ trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 113：2448-2456, 2008

11）Ueno H, Kosuge T, Matsuyama Y, et al：A randomized phase Ⅲ trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer：Japanse Study Group of adjuvant therapy for pancreatic cancer. Br J Cancer 101：908-915, 2009

12）Neoptolemos JP, Stocken DD, Bassi C, et al：Adjuvant chemotherapy with fluorouracil plus folic acid vs gemcitabine following pancreatic cancer resection. JAMA 304：1073-1081, 2010

13）Uesaka K, Fukutomi A, Boku N, et al：Randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer（JASPAC-01 study）. J Clin Oncol 30：2012（suppl 34；abstr 145）

14）Artinyan A, Anaya DA, McKenzie S, et al：Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 117：2044-2049, 2011

15）Motoi F, Unno M, Takahashi H, et al：Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer：Projecto study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 21：148-158, 2014

16）Evans DB, Varadhachary GR, Crane CH, et al：Preoperative gemcitabine-based chmoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26：3496-3502, 2008

17）Varadhachary GR, Wolff RA, Crane CH, et al：Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26：3487-3495, 2008

18）Heinrich S, Pestalozzi BC, Shager M, et al：Prospective phase Ⅱ trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of pancreatic head. J Clin Oncol 26：2526-2531, 2008

19）Palmer DH, Stocken DD, Hewitt H, et al：A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer：gemcitabine alone versusu gemcitabine combined with cisplatin. Ann Surg Oncol 14：2088-2096, 2007

20）Ohigashi H, Ishikawa O, Eguchi H, et al：Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 250：88-95, 2009

21）Motoi F, Ishida K, Fujishima F, et al：Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma：Results from a prospective multi-insitutional phase 2 trial. Ann Surg Oncol 20：3794-3801, 2013

22）Satoi S, Yamaue H, Kato K, et al：Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments：results of a project study of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20：5910-600, 2013

23）Katz MHG, Pisters PWT, Evans DB, et al：Borderline resectable pancreatic cancer：The importance of this emerging stage of disease. J Am Coll Surg 206：833-848, 2008

24）Bickenbach KA, Gonen M, Laura H, et al：Downstaging in pancreatic cancer：a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol 19：1663-1669, 2012

25）Conroy T, Desseigne F, Ychou M, et al：FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Endl J Med 364：1817-1825, 2011

26）Von Hoff DD, Ervin T, Arena FP, et al：Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369：1694-1703, 2013